IBT’s IBP-9414 Neonatal Trial Results Published in Leading Pediatric Journal

Infant Bacterial Therapeutics AB ( ($SE:IBT.B) ) has shared an update.

Infant Bacterial Therapeutics has published pivotal Phase III results from its Connection Study of IBP-9414 in very low birth weight infants in the journal Pediatric Research. The peer-reviewed data show that IBP-9414 was safe and reduced both all-cause mortality and surgically confirmed necrotizing enterocolitis, with the Phase III trial previously demonstrating a 27% mortality reduction versus placebo, underscoring the drug’s potential to improve outcomes and address a major unmet need in neonatal care.

The publication in a leading pediatric journal and the therapy’s earlier Breakthrough Therapy and Rare Pediatric Disease designations strengthen IBT’s position in the emerging field of live biotherapeutic products for fragile preterm infants. Successful development and eventual widespread use of IBP-9414 could save thousands of premature babies globally and enhance the company’s standing as a key innovator in treatments for conditions where effective therapies are currently lacking.

The most recent analyst rating on ($SE:IBT.B) stock is a Hold with a SEK48.00 price target. To see the full list of analyst forecasts on Infant Bacterial Therapeutics AB stock, see the SE:IBT.B Stock Forecast page.

More about Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB is a Stockholm-based pharmaceutical company focused on developing and commercializing drugs for diseases affecting premature babies. Its lead candidate, IBP-9414, is a formulated bacterial strain from human breast milk and is expected to be among the first live biotherapeutic products for premature infants, alongside a pipeline addressing other severe neonatal conditions.

Average Trading Volume: 7,005

Technical Sentiment Signal: Sell

Current Market Cap: SEK677.6M

For detailed information about IBT.B stock, go to TipRanks’ Stock Analysis page.